Cohen's SAC Capital Wants A Higher Bid for Pharmion (PHRM)
In an amended 13D filing on Pharmion Corporation (Nasdaq: PHRM) after the close, Steven Cohen's SAC Capital, an 8.3% holder, disclosed a letter sent to the company saying the proposed merger with Celgene (Nasdaq: CELG) undervalues the company and they believe the merger consideration should be increased if shareholders are not given the opportunity to assess competitive data from the Phase III Dacogen EORTC study, or else the vote should be delayed to give shareholders that opportunity.
In the letter, SAC Capital said, "If the Dacogen trial fails or produces data that are clearly worse than Vidaza's survival data, we believe Pharmion would be worth $80 - $100 or more as a standalone company versus the $72 per share in stock and cash offered by Celgene."
Shares of Pharmion are currently trading at around $69.
In the letter, SAC Capital said, "If the Dacogen trial fails or produces data that are clearly worse than Vidaza's survival data, we believe Pharmion would be worth $80 - $100 or more as a standalone company versus the $72 per share in stock and cash offered by Celgene."
Shares of Pharmion are currently trading at around $69.
You May Also Be Interested In
- UPDATE: SAP's (SAP) America Unit to Buy Ariba (ARBA) for $45/Share
- UPDATE: InterMune (ITMN) to Divest ActImmune for $55M in Cash, Plus Two-Year Royalty Stream
- UPDATE: Eaton (ETN) to Buy Cooper Industries (CBE) in Cash, Stock Deal Valued at $72/Share
Create E-mail Alert Related Categories
13Ds, Mergers and Acquisitions, RumorsRelated Entities
SAC Capital, Steven A. CohenSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
